Interleukin-6 (IL-6) receptor antibody therapy to malignant pleural mesothelioma

白细胞介素-6（IL-6）与类风湿性关节炎有关。托珠单抗（Actemra：人源化抗IL-6 R抗体）用于类风湿性关节炎治疗。我们研究了托珠单抗治疗恶性胸膜间皮瘤的效果。托珠单抗抑制恶性胸膜间皮瘤细胞生长，减少10- 25%。我们比较了培美曲塞、顺铂和托珠单抗的联合作用。培美曲塞、顺铂和托珠单抗的联合治疗效果优于其他任何两种药物的联合治疗。我们已经证实了MEK抑制剂的作用。我们检查了托珠单抗和MEK抑制剂的组合效果。托珠单抗和MEK抑制剂的组合抑制恶性胸膜间皮瘤细胞生长超过单次施用MEK抑制剂。托珠单抗将phosho-Stat 3表达降低至1/3-1/5。托珠单抗和MEK抑制剂的组合减少更多的phosho-Stat 3表达。

Interleukin-6 (IL-6) is associated with rheumatoid arthritis. Tocilizumab (Actemra : a humanized anti-IL-6R antibody) is used for rheumatoid arthritis therapy. We investigated the effect of tocilizumab to malignant pleural mesothelioma. Tocilizumab suppressed malignant pleural mesothelioma cell growth and reductions were 10-25%. We compared the combination effect of pemetrexed, cisplatin and tocilizumab. The combination of pemetrexed, cisplatin and tocilizumab was more effective than any other two drugs combinations. We have already conformed the effect of MEK inhibitor. We checked the combination effect of tocilizumab and MEK inhibitor. The combination of tocilizumab and MEK inhibitor suppressed malignant pleural mesothelioma cell growth more than a single administration of MEK inhibitor. Tocilizumab reduced the phosho-Stat3 expression to 1/3-1/5. The combination of tocilizumab and MEK inhibitor reduced more the phosho-Stat3 expression.